The fight for Complete Genomics and the demise of Helicos

Bloomberg reported last week that Illumina, one of the leaders in genetic sequencing technology, has offered $3.30 a share for Complete Genomics. The price is 5% higher than the bid from BGI-Shenzhen, which was accepted by the board of Complete Genomics in September (see the October 4, 2012 CHBP). I...

This research is archived and therefore no longer available. For further assistance please contact your Customer Success Manager or email Thank you!

Related Research

Cardea Bio

Company Profile | December 13, 2020

Offers graphene‑based lab‑on‑a‑chip biosensor systems, including biology‑gated graphene field‑effect transistors that allow for electronic chipsets built with molecular biology (e.g., integrating clustered regularly interspaced short palindromic repeats [CRISPR]), electronic devices, AI and ... To read more, click here.

Illumina hit with further European Commission antitrust investigations over $8 billion bid for Grail

News Commentary | August 02, 2021

Grail, originally a spinoff of Illumina, develops early‑detection cancer diagnostics using blood samples, which the genomics company seeks to add back into its biotech arsenal. However, both the European Commission and the U.S. Federal Trade Commission argue that the takeover could harm competing ... Not part of subscription


Company Profile | May 13, 2022

​​​​​Develops a rapid pathogen detection platform,TrueRapid; the system works by selectively capturing only live pathogenic bacteria cells by binding to aptamers Claims the system is capable of delivering quantitative analysis for the presence of food pathogens in 20 minutes and reducing the ... Not part of subscription